KRAS and non-small cell lung carcinoma: Here, a proof-of-concept experiment was performed to show that BOLT-seq can be used in a large-scale screen for drug-induced perturbation of gene expression in NIC-H358 cells, which are KRAS G12C mutant non-small cell lung carcinoma cells.